{"id":890042,"date":"2026-10-21T22:28:15","date_gmt":"2026-10-21T22:28:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/890042\/"},"modified":"2026-10-21T22:28:15","modified_gmt":"2026-10-21T22:28:15","slug":"revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/890042\/","title":{"rendered":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/27b8bd06495b314d44156768043f309f433b697fbf524a0aefca4f1b4c0ca979\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fglobenewswire.com%2F5fd0263e2225a1c8e4ed2273768d4bce.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Revolution Medicines, Inc.\" height=\"100\" width=\"300\" class=\"yf-1f8hkhu loader\"\/><\/a> Revolution Medicines, Inc.           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">REDWOOD CITY, Calif., Oct. 21, 2026 <a href=\"https:\/\/www.globenewswire.com\" data-ylk=\"slk:(GLOBE%20NEWSWIRE);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;(GLOBE NEWSWIRE)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">(GLOBE NEWSWIRE)<\/a> &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines&#8217; senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">To listen to the live webcast, or access the archived webcast, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9f3UUGb08W_6tJS-pCEN73Fz15cc-wKY6adlrXYjjjzNDVK-Y3o0aVvx_RNozk9dkrPYaBvx8qJaYLdUbIzgfJWWMKm2wSf3CCLQvmtn-j0US_hpeBFuz7sOhhtFm5IjDlYhQ6DaSpiCYO4ZsBg2kKCTemyX0KppY2tOiYlnyOOy4wjcfSUfI0Pgkd7yWJZXHn36yIyrr0pOCr7muRi7sXjaf8lW8PUlxi-YkNltHpjt0XaFOiaAWWbpsT29ZBf6sJouDQhG-1jNnTss5PiVCXgNAyWb0vbfw6t_diXQ782KMGEn7J8Tpnv0RLge48vHW_XxhAQ9HoOvXkVPzwZMrjfUsb0cIK19oiUNIOOh1ol-NtjEbwqcjTq2Ps-iClSn\" data-ylk=\"slk:https%3A%2F%2Fir.revmed.com%2Fevents-and-presentations;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;https:\/\/ir.revmed.com\/events-and-presentations&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcast, a replay will be available on the company&#8217;s website for at least 14 days.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">About Revolution Medicines, Inc.<br \/>Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ybjz5GKdCaFlAAlIOSXWmibhmUa47DNAFC3VtEyHts_9iCbMpkEj24KApRb8zJZAikQ1l1ogOMWdNjIZI3C6BZNLYy_aBxFl2l48C7HZI2ZE14EOW3QVIVvApnSxFzsBSY4L9WkjatIJbEfcNcQEnWWdilOPr3Z5LyQUoXQCy5NRPA4OiKnrULcu8WI-plVi7gJUcrQVgRMs2V4HaEiqwS8L5p1MxVAfN3aISLUtxljCMHgN91nJWYSF-TXKZiHdLVfx6RJ1cbpRYiYqkv43krIgiew3guJEBr-7jN4wDzXN_zzHCp39j3-5f2-NVtoaqUEUqOlXN3bWWu1NdqmfNNza-jswDJd7jFtlU8SQcFknt2QZnNWxNfjiqSHvfgmNh7aHnawj4KUL-y4_sKWkvDNZnL5S4CycqCrbWC-p_Lk=\" data-ylk=\"slk:www.revmed.com;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;www.revmed.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">www.revmed.com<\/a> and follow Revolution Medicines on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xT80E3bLZDNc8IppLtOCo6qPdTb6txtvBN-jfAsR74JyICI0tuGD8vm1qIVJMx2CLNStwEGKcN1IeHVfQl8e0PV1HgDtAxJrh-GaJkZ-VAYa5QZbpU-S7XMmw7PHFnqNKRk5A-Apb4Rzom0snxaYviSk4isRM38KaGCIxaKlq1jqR4jHrqOgiuHKrVI8fDrgOAk07fp3wCvCSCOJYhVOXeYexZrgMD9z8jXTQzW0dZc3wthvpdE47oxl8MYNH6oyC6rzDfEqjZUhwQQBNjv_abBOQOijEWNAu_IKcJilHJa0djirWqLA8nFQOdL5zdysisv4ypD5watGDAol9ibJN8G3yA95uycYCuK_R8AnCrElH15oyXMy8HybReUtgV7GiexCzRrw8s44GUOffdXZtxNZB3flQAoxpKDyDnhkriJCn1YxDGE2o7rZ4UkkKleUNKdDPEkSsKoH-ylXAFAFkqK_-PqjmmgeeRffzFcsJH0=\" data-ylk=\"slk:LinkedIn;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;LinkedIn&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RKbsyNt7fF69XkPPGzyMEyDh7HZV1YACf5ElfNBiFzOp4rYgr6zNylM8GHiwdetAVImpct1RO2LOftElHqOhJMgaYNJYCHFSxwRONj_dltESTxzWHakF_71SUuvZ9LK2v9WpgGeKtDKCiK3uCp0ArDnQNgt1NJo10kQKBpAUAq_6RZ_WoOkTEI6NFH3VBzH6VvFC2yYn_mTnO9gzMWFkP4ovMR_IpsUsNbAva_nH6cBo1ukne_i1MYI3NsHyJyYj_Akd4UE0i69GLW8aBUuNJnhXwolfeO636JHuynIvjigZE0YtBGgHE0I7CuRjFNmPgFo4tovVjw-D0fRv49qYaJKhERgvEYhimCRbjeItgM5T3wp9n89v2Eiz7AmZIYUs\" data-ylk=\"slk:X;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;X&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">X<\/a> (Twitter) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5O47gI4VgRJxUMr_uyXKkSwiI-FLqZQ_rpkJLxebqP2uj9Jexho4cA8MxHwmddM1VXV4hFmssNoUe7M8xTGSB_c8-p-83k0lk0mxOBuXkpccTdVRS_G0wwdXbod6h4fO7WfSpf4KxfBmIfD3fuCFQm6k1jll6A5NO6H5AEMz4EIpCykDYiJG3IrkDa2_iNeNnxNf8oiGmSGA24dSQnx-YtVG6hGNJQJWrqrQg8xG8Fh9-4O8DZhRMcyWNt1UzyR1nrGfpYNDeoYfl0Gcwxxsryt_EnqVV5ULN3y8KbMHbQ2M4uFddy7dMfOoDIIgkrrt2aIHNh9_6Bzn5gbuJTfbBi0UxhGQbFTSBgzCqr-p8y0bMXEgvrqHZbv3bNZdW2dhBBU9fdYnNra9yuQpGJiDudi76h73oiTZW_naJUVJp1r1y1hu5jnj53LO9vzNCGbSzfONp0sQCiZDcpd5XyNAhIqwhm_rNFFgFVyVDB_m0Ak=\" data-ylk=\"slk:Instagram;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Instagram&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Instagram<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Revolution Medicines Media &amp; Investor Contact:<br \/>media@revmed.com<br \/>investors@revmed.com  <\/p>\n","protected":false},"excerpt":{"rendered":"Revolution Medicines, Inc. REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a&hellip;\n","protected":false},"author":2,"featured_media":890043,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[5097,28,122,101,939,2993,2994,32455,2995,932,112,32456,20112,147,9323,1170,1666,6480,2996,2997,923,19533,3733,32457],"class_list":["post-890042","post","type-post","status-publish","format-standard","has-post-thumbnail","category-markets","tag-401k","tag-business","tag-business-news","tag-economy","tag-finance","tag-financial-information","tag-investing","tag-investment-tools","tag-investor","tag-market-news","tag-markets","tag-mortgage","tag-mutual-funds","tag-personal-finance","tag-quote","tag-real-estate","tag-retirement","tag-stock","tag-stock-research","tag-stock-valuation","tag-stocks","tag-suze-orman","tag-tax","tag-track-portfolio"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/890042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=890042"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/890042\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/890043"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=890042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=890042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=890042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}